INSTITUT Inactive Instrument
INSTITUT Stock Moscow Micex - RTS
Equities
ISKJ
RU000A0JNAB6
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 04-26 | Artgen Biotech PJSC Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Artgen Biotech PJSC Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.14B 12.41M 17.08M | Sales 2023 | 1.37B 14.94M 20.56M | Capitalization | 4.42B 48.25M 66.38M |
|---|---|---|---|---|---|
| Net income 2022 | 46M 502K 691K | Net income 2023 | 169M 1.85M 2.54M | EV / Sales 2022 | 4.3 x |
| Net Debt 2022 | 605M 6.6M 9.08M | Net Debt 2023 | 242M 2.64M 3.64M | EV / Sales 2023 | 3.41 x |
| P/E ratio 2022 |
112
x | P/E ratio 2023 |
32.7
x | Employees | - |
| Yield 2022 |
1.68% | Yield 2023 |
-
| Free-Float | 22.77% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 54 | 03-11-26 | |
| Director of Finance/CFO | - | - | |
| Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrey Isaev
BRD | Director/Board Member | 53 | 07-06-27 |
| Director/Board Member | 65 | 04-01-04 | |
Sergey Kiselev
BRD | Director/Board Member | 66 | 07-06-27 |
Institut Stvolovykh Kletok Cheloveka PAO (Human Stem Cells Institute OJSC or HSCI OJSC) is a Russia-based company engaged in the research and development, as well as commercialization and marketing of proprietary products and services in the areas of cell-based and gene and post-genome technologies. The Company is engaged in such projects as: Gemabank, cord blood stem cells bank; Gemascreen medical genetic diagnostics and consulting services provided by the Company domestically with the aim of early detection, treatment or prevention of inherited diseases; SPRS-therapy service a set of personalized diagnostics and treatment procedures; SynBio, which focuses on development of new medicines. In addition, the Company is a producer of Neovasculgen, a gene-therapy drug. In February 2014, it opened a biotech complex in Kyiv.
| 1st Jan change | Capi. | |
|---|---|---|
| +17.18% | 85.55B | |
| -28.48% | 70.07B | |
| +6.76% | 28.95B | |
| -7.44% | 17.51B | |
| +2.14% | 17.39B | |
| +2.10% | 15.38B | |
| +7.02% | 13.4B | |
| +64.96% | 12.93B | |
| +6.64% | 12.77B |
- Stock Market
- Equities
- ISKJ Stock
- ISKJ Stock